K201 compound

05/01/1999 - "The aim of this study was to investigate the potential protective effect of JTV519 on myocardium subjected to prolonged ischemia and the underlying mechanism of such protection. "
03/01/2002 - "Furthermore, JTV-519 showed significant potential for improving myocardial relaxation during ischemia. "
03/01/2002 - "In conclusion, JTV-519 has a significant beneficial effect on myocardial energy metabolism during both ischemia and reperfusion. "
03/01/2002 - "After 20 min normothermic global ischemia, postischemic reperfusion was carried out for 30 min. JTV-519 was administered from 40 min prior to the global ischemia. "
10/01/2000 - "Normothermic, 20-min, global ischemia was followed by 30-min of postischemic reperfusion and JTV-519 was administered from 40 min prior to the global ischemia. "

01/28/2003 - "Heart failure was produced by 4 weeks of rapid right ventricular pacing, with or without JTV519; SR were then isolated from dog left ventricular (LV) muscles. "
12/01/2004 - "In heart failure (HF), there is excessive disassociation of calstabin2 from the RyR2 receptor, and JTV519 has been shown to be beneficial in an animal model of HF. "
01/28/2003 - "During the development of experimental heart failure, JTV519 prevented the amount of RyR-bound FKBP12.6 from decreasing. "
10/01/2005 - "In human atrial fibrillation and heart failure, where there is excessive disassociation of calstabin2 from the RyR2 receptor in vitro, JTV519 is able to reverse this. "
03/01/2003 - "A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure."

08/01/2003 - "JTV-519 significantly decreased the mean number of sustained atrial fibrillation episodes (from 4.2 +/- 2.9 to 0 +/- 0, P < 0.01). "
08/01/2003 - "The inducibility of atrial fibrillation/flutter, the atrial effective refractory period, and the intra-atrial conduction time were compared before and after the continuous infusion of JTV-519 (0.03 mg/kg/min). "
12/01/2000 - "We also evaluated the effects of JTV-519 on experimental atrial fibrillation (AF) in isolated guinea-pig hearts. "
08/01/2003 - "JTV-519 had significant protective effects on atrial fibrillation in the canine sterile pericarditis model, mainly by increasing effective refractory period, suggesting that it may have potential as a novel antiarrhythmic agent for atrial fibrillation."
08/01/2003 - "We investigated the antiarrhythmic effects of JTV-519 on atrial fibrillation/flutter in the canine sterile pericarditis model. "

03/01/2003 - "Here, we assess whether the new cardioprotective agent JTV519 can correct it in tachycardia-induced HF. "
01/01/2020 - "Lower calsequestrin 2 protein levels, faster diastolic depolarization (DD) and efficacy of JTV-519 (46% at 1 µmol/L) to terminate tachycardia indicate alterations of Ca2+ handling being part of the underlying mechanism. "

08/01/2003 - "JTV-519 had significant protective effects on atrial fibrillation in the canine sterile pericarditis model, mainly by increasing effective refractory period, suggesting that it may have potential as a novel antiarrhythmic agent for atrial fibrillation."
08/01/2003 - "We investigated the antiarrhythmic effects of JTV-519 on atrial fibrillation/flutter in the canine sterile pericarditis model. "
08/01/2003 - "Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model."